1,269
Participants
Start Date
April 30, 2006
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
Buprenorphine/naloxone
Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
Methadone
Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
Addiction Research & Treatment Corp, Brooklyn
NET Steps, Philadelphia
Matrix Institute, Los Angeles
BAART; Turk Street Clinic, San Francisco
Bi-Valley Medical Clinic INC., Sacramento
CODA-Research, Portland
Evergreen Treatment Services, Seattle
Hartford Dispensary, Hartford
CT Counseling Centers, Waterbury
National Institute on Drug Abuse (NIDA)
NIH
University of California, Los Angeles
OTHER